The present invention relates generally to stabilization of one or more thrombocytes at ambient temperatures. In particular, the invention relates to formulations, compositions, articles of manufacture, kits and methods for substantially stable storage of one or more metabolically-active thrombocytes at ambient temperatures.
Whole blood is a complex mixture of cells, nucleic acids, proteins and various other analytes. In particular, blood components include, but are not limited to: cells, such as leukocytes (monocytes, lymphocytes and granulocytes), erythrocytes, thrombocytes and circulating tumor cells; nucleic acid molecules, such a circulating-free DNA (cfDNA); polypeptides, such as lipoproteins, albumin and serum proteins, and other various analytes.
Thrombocytes or platelets are anucleated cells that play a key role in the clotting of blood. Thrombocytes are small, disc-like cells that circulate in mammalian blood and are involved in hemostasis. Thrombocytes secrete a wide variety of growth factors that assist in promoting blood clotting and tissue regeneration.
The level of circulating thrombocytes in a healthy individual is controlled within a physiological range of about (150-400)×103 per mm3. Suboptimal levels of thrombocytes (thrombocytopenia) can lead to excessive bleeding, whereas levels exceeding optimal concentrations can lead to the formation of thromboli (blood clots) that can obstruct blood vessels and can lead to higher risk of stroke, pulmonary embolus or myocardial infarction.
Circulating thrombocytes are typically present in an inactivated state, and are maintained in the inactivated state by factors produced by endothelial cells lining the blood vessel lumen. Upon disruption or injury to this endothelial layer, thrombocytes come in contact with collagen or von Wildebrand's factor, which activates the thrombocytes causing the thrombocytes to aggregate (i.e., clot). This activation and aggregation also may occur by the enzymatic activity of thrombin or in the presence of ADP. Upon activation, thrombocytes release the contents of alpha and dense granules that include growth factors and fibrinogen that assist in clot formation and help promote recruitment of fibroblasts to promote wound healing. Activated thrombocytes can be distinguished from inactivated thrombocytes by their more spherical/stellate shape.
The activation, aggregation and/or release of numerous growth factors and other intracellular components of thrombocytes during the collection of whole blood can greatly hinder the quantitation and analysis of these cells. The addition of various anti-coagulants to maintain an inactivated thrombocytes at ambient temperatures results in only about 13-52% inactivated thrombocytes at 24 hours making accurate quantitative analysis of total thrombocytes essentially impossible at this time point. Thus, there exists a need for improved formulations for and methods of stabilizing thrombocytes at ambient temperatures for a time sufficient for storage and shipping thrombocytes for research, diagnostic and therapeutic purposes.
The formulations, compositions and methods of the present invention advantageously provide for the stabilization of thrombocytes at ambient temperatures and these cells remain functional and retain the ability to be activated post-blood collection for a period of at least 24 hours, significantly increasing the time for storage and shipping of substantially stable thrombocytes for research, diagnostic and potential therapeutic applications. Disclosed herein in some embodiments, are formulations for substantially stable storage of one or more thrombocytes at ambient temperatures, wherein the one or more thrombocytes are stabilized for a period of at least six hours. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, the one or more thrombocytes are in a blood sample. In some embodiments, the one or more thrombocytes are in an inactivated state in a blood sample. In some embodiments, the one or more thrombocytes are isolated from a blood sample. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least nine hours. In some embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In some embodiments, the formulation comprises: (i) a pH buffer; (ii) an anti-coagulant; (iii) at least one non-reducing sugar or polyol; and (iv) a functionalized carbohydrate. In some embodiments, the formulation comprises a polyol selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol and inositol, and combinations thereof. In some embodiments, the polyol is a pentose polyol or a hexose polyol. In some embodiments, the pentose polyol is adonitol. In some embodiments, the functionalized carbohydrate is sucralfate or sucrose octasulfate. In some embodiments, the functionalized carbohydrate is sucrose octasulfate. In some embodiments, the non-reducing sugar is sucrose or trehalose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the anticoagulant is EDTA or hirudin. In some embodiments, the pH buffer is 2× phosphate buffered saline or Tris-HCl.
In one aspect of the invention, formulations are provided for substantially stable storage of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures, wherein the one or more thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In certain embodiments, the formulation comprises (i) a pH buffer, (ii) an anticoagulant, (iii) at least one non-reducing sugar or polyol, and (iv) a functionalized carbohydrate. In some embodiments, the polyol is selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol inositol, and combinations thereof. In some embodiments the polyol is a pentose polyol or a hexose polyol. In some embodiments, the polyol is adonitol. In some embodiments, the functionalized carbohydrate is sucralfate or sucrose octasulfate. In some embodiments, the functionalized carbohydrate is sucrose octasulfate. In some embodiments, the non-reducing sugar is sucrose or trehalose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the anticoagulant is EDTA or hirudin. In some embodiments, the anticoagulant is EDTA, the functionalized carbohydrate is sucralfate or sucrose octasulfate, and the non-reducing sugar is sucrose or trehalose. In yet other embodiments, the anticoagulant is EDTA, the functionalized carbohydrate is sucrose octasulfate and the non-reducing sugar is trehalose. In some embodiments, the pH buffer is 2× phosphate buffered saline or Tris-HCl. Disclosed herein, in some embodiments are formulations for substantially stable storage of one or more thrombocytes at ambient temperatures, comprising a halogenated disaccharide derivative and an anticoagulant, wherein the one or more thrombocytes are stabilized for a period of at least six hours. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, the one or more thrombocytes are in a blood sample. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state in a blood sample. In some embodiments, the one or more thrombocytes are isolated from a blood sample. In some embodiments, the anticoagulant is hirudin. In some embodiments, the halogenated disaccharide derivative is selected from the group consisting of sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, 1,6-sichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and combinations thereof. In some embodiments, the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).
In some embodiments, there are provided formulations for substantially stable storage of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures, comprising a halogenated disaccharide derivative, wherein the one or more thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, the halogenated disaccharide derivative preferably is selected from the group consisting of sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and more preferably the halogenated disaccharide derivative is sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside). In some embodiments, the formulations further comprise an anticoagulant, preferably hirudin. In some embodiments, the anticoagulant is hirudin. In some embodiments, the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).
Disclosed herein in some embodiments, are compositions of substantially, stably stored one or more thrombocytes comprising one or more thrombocytes admixed with a disclosed formulation. In some embodiments, the one or more thrombocytes are in a blood sample. In some embodiments, the one or more thrombocytes are isolated thrombocytes. In some embodiments, the one or thrombocytes are in an inactivated state.
Disclosed herein in some embodiments, are articles of manufacture, comprising a formulation described herein contained within a blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube.
Disclosed herein, in some embodiments, are kits comprising an article of manufacture described herein and a package insert.
Disclosed herein in some embodiments, are methods for substantially stable storage of one or more thrombocytes at ambient temperatures, comprising: admixing the one or more thrombocytes from a subject with a formulation provided herein, wherein the one or more thrombocyte is stabilized for a period of at least six hours. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, the one or more thrombocytes are in a blood sample from the subject. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state in a blood sample from the subject. In some embodiments, the one or more thrombocytes are isolated from a blood sample from the subject. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least nine hours. In some embodiments, the method further comprises activating the one or more thrombocyte in an inactivated state, by the addition of an activating agent to promote thrombocyte aggregation. In some embodiments, the activating agent is ADP. In some embodiments, the method further comprises activating the one or more thrombocyte by the addition of an activating agent to promote thrombocyte aggregation. In some embodiments, the activating agent is ADP. In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human.
Disclosed herein in some embodiments, are methods for substantially stable storage of one or more thrombocyte in an inactivated state in a blood sample at ambient temperatures, comprising, admixing a blood sample from a subject with a formulation provided herein, wherein the one or more thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In some embodiments, the blood sample is admixed with the stabilization formulation at the time the blood sample is collected from the subject to substantially stabilize the one or more thrombocytes in the inactived state post collection from the subject. In some embodiments, the method further comprises activating the one or more thrombocytes by the additional of an activating agent. In some embodiments, the activating agent is ADP. In further embodiments of the methods, the subject is an animal, more preferably a mammal, and even more preferably a human.
The present invention relates to formulations, compositions, articles of manufacture, kits, and methods for substantially stable storage of one or more thrombocyte at ambient temperatures. In some embodiments, the one or more thrombocytes are stored in an inactivated, but activatable, state in a blood sample. In one aspect, the formulations described herein beneficially maintain the integrity of inactivated, metabolically active, thrombocytes that may be subsequently analyzed for activation or that may be used in therapeutic applications for promoting blood clotting in a patient.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and/or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
“About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, or ±5%, or even ±1% from the specified value, as such variations are appropriate for the disclosed compositions or to perform the disclosed methods.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, patent applications and publications referred to herein are incorporated by reference in their entirety.
Formulations are provided, in some embodiments, for substantially stable storage of metabolically-active thrombocytes at ambient temperatures. In some embodiments, the thrombocytes are isolated from a blood sample. In some embodiments, the thrombocytes are in a blood sample. In some embodiments, the thrombocytes are inactivated. In certain embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain other embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a polyol and a functionalized carbohydrate. In certain other embodiments, the stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative, an anticoagulant, and a pH buffer. The formulations are capable of stabilizing at least 60%, 70%, 80% or even 90% inactivated, metabolically-active thrombocytes in a blood sample at ambient temperatures for a period of at least 6 hours, or at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours.
The term “ambient temperature” as used herein refers to common indoor room temperatures. In some embodiments, ambient temperature is 15 to 32° C. In some embodiments, ambient temperature is 20 to 27° C.
In another aspect of the present invention, formulations are provided for substantially stable storage of inactivated, metabolically-active thrombocytes in a blood sample at ambient temperatures. In certain embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain other embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a polyol, and a functionalized carbohydrate. In certain other embodiments, the stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative, an anticoagulant, and a pH buffer. The formulations are capable of stabilizing at least 60%, 70%, 80% or even 90% inactivated, metabolically-active thrombocytes in a blood sample at ambient temperatures for a period of at least 6 hours, or at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours.
In another aspect, compositions are provided herein in which a blood sample is admixed with a thrombocyte stabilization formulation to produce substantially stable one or more inactivated thrombocytes in a whole blood preparation. In still other embodiments, a composition comprising purified or substantially purified one or more thrombocyte admixed with a stabilization formulation of the present invention are provided.
A. pH Buffers
According to certain embodiments, the herein described formulations and compositions for substantially stable storage of one or more thrombocytes include one or more pH buffers. In some embodiments, the pH buffer is any of a large number of compounds known in the art for their ability to resist changes in the pH of a solution, such as in an aqueous solution in which the pH buffer is present. Selection of one or more particular pH buffers for inclusion in a stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including the pH that is desired to be maintained, the nature of the biological sample, the solvent conditions to be employed, the other components of the formulation to be used, and other criteria. For example, typically a pH buffer is employed at a pH that is within about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 pH unit of a proton dissociation constant (pKa) that is a characteristic of the buffer.
Non-limiting examples of pH buffers include citric acid, tartaric acid, malic acid, sulfosalicylic acid, sulfoisophthalic acid, oxalic acid, borate, CAPS (3-(cyclohexylamino)-1-propanesulfonic acid), CAPSO (3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid), EPPS (4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid), HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), PIPES (1,4-piperazinediethanesulfonic acid), TAPS (N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid), TAPSO (2-hydroxy-3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid), TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), bicine (N,N-bis(2-hydroxyethyl)glycine), tricine (N-[tris(hydroxymethyl)methyl]glycine), tris (tris(hydroxymethyl)aminomethane) and bis-tris (2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-1,3-propanediol). In some embodiments, including any of those set forth in Table 1, have a pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0.
B. Polyols
Also as described herein, certain embodiments include at least one polyol in the composition for substantially stable storage of viable, inactivated thrombocytes in a whole blood sample at ambient temperatures. Polyols are polyhydric alcohols containing two or more hydroxyl groups and have the general formula H(CHOH)nH, wherein n is an integer selected from 2 to 7 inclusive. Polyols differ in chain length with most polyols having five- or six carbon chains being derived from pentoses (five-carbon sugars) and hexoses (six-carbon sugars); however shorter and longer carbon chain polyols also exist. Exemplary polyols include, but are not limited to, glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol and inositol. Selection of one or more particular polyols for inclusion in a substantially stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including other formulation components. In certain embodiments, the polyol present in the formulation is a pentose polyol. In some embodiments, the polyol is adonitol. In some embodiments, the polyol is present at a concentration between 20-100 mM, or between about 25-75 mM. In some embodiments, the polyol is a pentose polyol and is present at a concentration between 20-100 mM, or between about 25-75 mM. In some embodiments, the polyol is adonitol and is present at a concentration between 20-100 mM, or between about 25-75 mM.
C. Disaccharide Derivatives
In certain embodiments, the formulations or compositions for substantially stable storage of one or more inactivated thrombocyte in a whole blood sample at ambient temperatures, including those in Table 1, include at least one halogenated disaccharide derivative. In some embodiments, the halogenated disaccharide derivative is a di- or tri-chlorinated disaccharide. In some embodiments, such di- or tri-chlorinated disaccharides unexpectedly are capable of substantially stable storage of inactivated thrombocytes either alone or in the presence of only a buffer. Halogenated disaccharide derivatives are known, e.g., see US Patent Publication No. 2014/0065062, and include sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside. Selection of one or more particular halogenated disaccharide derivative for inclusion in a substantially stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including other formulation components. In some embodiments, the functionalized carbohydrate is sucralose and is present at about 1.0-50.0 mM. In some embodiments, the functionalized carbohydrate is sucralose and is present at about 10.0-30.0 mM. In some embodiments, the functionalized carbohydrate is sucralose and is present at about 25.0 mM.
D. Functionalized Carbohydrates
In some embodiments described herein, the formulations, including those in Table 1, include a functionalized carbohydrate. Exemplary functionalized carbohydrates include sucralfate or sucrose octasulfate and it will be appreciated that from the present disclosure the skilled person may select other functionalized carbohydrates for use in a stable storage formulations and compositions for viable, activatable, thrombocytes, as may vary based on the other components of the composition that are employed. In some embodiments, the concentration of functionalized carbohydrates in the present formulations and compositions, including those set forth in Table 1, is about 0.005-1.0 mM. In some embodiments, the concentration of functionalized carbohydrates in the present formulations and compositions, including those set forth in Table 1, is about 0.25-0.5 mM.
E. Non-Reducing Sugars
In some embodiments, the formulations and compositions for substantially stable storage of thrombocytes at ambient temperatures include at least one non-reducing sugar. In some embodiments, the formulations and compositions for substantially stable storage of viable, inactivated thrombocytes in a whole blood sample at ambient temperatures include at least one non-reducing sugar. As used herein, “non-reducing sugars” refers to carbohydrate molecules that lack a functional aldehyde group. Exemplary non-reducing sugars include sucrose and trehalose. In some embodiments, the non-reducing sugar is sucrose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the trehalose is present at a concentration of about 1.0-50 mM. In some embodiments, the trehalose is present at a concentration of about 10.0-30 mM. In some embodiments, the trehalose is present at a concentration of about 25 mM.
F. Anticoagulants
In some embodiments, an anticoagulant is included in the presently described formulations or compositions. Such anticoagulants are known in the art. Exemplary anticoagulants include ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate. In some embodiments, the anticoagulant is hirudin. In some embodiments, the hirudin is present at a concentration of about 1.0-50 μg/mL. In some embodiments, the hirudin is present at a concentration of about 1.0-25 μg/mL. In some embodiments, the hirudin is present at a concentration of about 10-20 μg/mL.
In some embodiments, the formulations, compositions and methods of the present invention advantageously provide for the substantially stable storage of thrombocytes at ambient temperatures for a period of at least six hours. In some embodiments, the formulations, compositions and methods of the present invention advantageously provide for the substantially stable storage of thrombocytes in their natural circulating, inactivated state in a blood sample at ambient temperatures, wherein the cells retain the ability to be activated post collection for a period of at least six hours. In other embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In other embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours.
In certain embodiments, the formulations for the substantially stable storage of thrombocytes at ambient temperatures comprise a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain embodiments, the stabilization formulations comprise a pH buffer, an anticoagulant, a polyol, and a functionalized carbohydrate. In certain embodiments, the formulations for the substantially stable storage of thrombocytes comprise a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In some embodiments, the formulations for the substantially stable storage of thrombocytes comprise a halogenated disaccharide derivative, and an anticoagulant, and may further comprise a pH buffer. In some embodiments, the anti-coagulant is sprayed and dried on the blood collection tube, container, or vessel prior to collection of the blood sample from the subject. In some embodiments, the anti-coagulant is added directly to the formulations described herein.
In certain embodiments, the pH buffer is Tris-HCl, the polyol is a pentose alcohol, the non-reducing sugar is trehalose, the anticoagulant is EDTA or hirudin, and the functionalized carbohydrate is sucrose octasulfate. In certain embodiments, the pH buffer is Tris-HCl, the polyol is adonitol, the non-reducing sugar is the D+ isomer of trehalose, the anticoagulant is EDTA or hirudin, and the functionalized carbohydrate is sucrose octasulfate. In certain embodiments, the pH buffer is Tris-HCl, the polyol is adonitol, the non-reducing sugar is the D+ isomer of trehalose, the anticoagulant is hirudin, and the functionalized carbohydrate is sucrose octasulfate. In some embodiments, the disaccharide derivative is a halogenated disaccharide and the anticoagulant is hirudin. In some embodiments, the halogenated disaccharide is sucralose and the anticoagulant is hirudin.
In some embodiments, the formulations for the substantially stable storage of inactivated thrombocytes at ambient temperatures include the exemplary formulations provided in Table 1.
In some embodiments, the exemplary Formulations A-F of Table 1 are prepared using materials commercially available from suppliers and preparing such formulations is accomplished using the methods disclosed herein as well as other methods known to those skilled in the art.
In some embodiments, pre-weighed solid components are added to a suitable vessel, such as a square bottle, to which the aqueous components are added. The reaction mixture is agitated, e.g., by shaking, until the solid components have completely dissolved and then the pH of the mixture is adjusted to the desired pH using a suitable acid, e.g., hydrochloric acid. The resulting formulations are then sterilized, e.g., using a 0.22 micron filter, and stored at room temperature.
In one example, a 50 mL preparation of a 20× Formula A is prepared as follows: 15.2034 gr of adonitol (Calbiochem, catalogue #121739) and 1.251 g sucrose octasulfate potassium salt (Toronto Research Chemicals, catal,ogue #S69900) are added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.51. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.
In another example, a 50 mL preparation of a 20× Formula B is prepared as follows: 7.5994 g of adonitol, 9.4997 g D-(+)-trehalose dihydrate (Fluka, catalogue #90210), and 1.25 g sucrose octasulfate potassium salt are added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.51. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.
In another example, a 50 mL preparation of a 20× Formula C is prepared as follows: 9.5003 g D-(+)-trehalose dehydrate and 1.2502 g sucrose octasulfate potassium salt are added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.52. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.
In another example, a 50 mL preparation of a 20× Formula D is prepared as follows: 7.5994 g of adonitol, 9.5003 g D-(+)-trehalose dihydrate and 0.625 g sucrose octasulfate potassium salt. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.51. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.
In another example, a 50 mL preparation of a 20× Formula E is prepared as follows: 9.9997 g of sucralose (Sigma, catalogue #69293) is added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved and hydrochloric acid is added to adjust the pH to 7.54. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.
In another example, a 50 mL preparation of a 20× Formula F is prepared as follows: 9.9993 g of sucralose (Sigma, catalogue #69293) is added to a square bottle. Water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, providing a solution having a pH of 7.54. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.
In some embodiments, the substantially stabilized one or more thrombocytes in a blood sample at ambient temperatures are purified using well known methods employed by those skilled in the art. Apparatus and kits for purifying thrombocytes from blood are well known (e.g., see U.S. Pat. Nos. 5,234,593; 6,315,706 and 7,708,152). In certain embodiments, the thrombocytes are purified using a bag PC (platelet concentrate) prepared after collection of blood in a bag and the apheresis PC obtained by the use of a component blood collecting device. These methods separate thrombocytes from blood using centrifugal separation. In some embodiments, substantially stabilized, intact, metabolically active viable cells are advantageously purified by affinity chromatography or by fluorescence activated cell sorting (FACS) analysis using antibodies generated against a native wild type membrane proteins and receptors, and which method is not possible using other storage formulations that denature these cellular proteins.
In some embodiments, the purified one or more thrombocyte are subsequently stored in the formulations described herein for extended periods before analysis or use.
In certain embodiments, articles of manufacture are provided, which comprise a formulation provided herein, contained within a suitable blood collection tube, container or vessel. In some embodiments, the formulation is selected from those set forth in Table 1. In some embodiments, these articles of manufacture are used for substantially stable storage of one or more blood component by stabilizing one or more blood component at the time of blood collection. In certain embodiments, the blood collection tube is an evacuated blood tube having less than atmospheric pressure to withdraw a predetermined volume of whole blood. In some embodiments, these articles of manufacture are used in the kits and methods described herein.
In certain embodiments, there are provided kits comprising any one of the articles of manufacture described herein and a package insert. In some embodiments, the components of the kit are supplied in a packaging means, such as a compartmentalized plastic enclosure, preferably with a hermetically sealable cover so that the contents of the kit can be sterilized and sealed for storage.
Described herein, in some embodiments, are methods for substantially stable storage of one or more thrombocyte at ambient temperatures. In some embodiments, the methods are for substantially stable storage of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures.
In certain embodiments, the methods comprise admixing a blood sample with a formulation for substantially stable storage of one or more thrombocyte at ambient temperatures for a period of at least six hours. In some embodiments, the one or more thrombocytes are isolated from a blood sample. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, at least 90% of the thrombocytes remain in an inactivated state for a period of at least six hours. In other embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In certain embodiments, the formulation is one of the formulations set forth in Table 1.
In certain embodiments, the methods comprise admixing a blood sample with a formulation for substantially stable storage of viable thrombocytes, wherein the formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol and a functionalized carbohydrate. In certain embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a polyol, and a functionalized carbohydrate. In certain embodiments, the stabilization formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulation comprises a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulation comprises a halogenated disaccharide derivative and an anticoagulant furthers comprise a pH buffer. In certain embodiments, the formulation is one of the formulations set forth in Table 1.
In certain embodiments, the methods comprise admixing a blood sample with a formulation for substantially stable storage of viable, activatable thrombocytes in a blood sample, wherein the formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain embodiments, the thrombocyte stabilization formulation comprises a pH buffer, an anticoagulant, polyol, and a functionalized carbohydrate. In certain other embodiments, the stabilization formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulation comprises a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulation further comprises a pH buffer. In certain embodiments, the formulation is one of the formulations set forth in Table 1.
Blood collection tubes, bags, containers and vessels are well-known in the art and have been employed by medical practitioners for decades. Blood collected for substantially stable storage of one or more blood component may be obtained from a subject, donor, or patient using any method or apparatus commonly employed by those skilled in the art such as venipuncture or finger prick. In some embodiments, when the blood is collected by venipuncture, a formulation described herein is located inside the blood collection tube, e.g., an evacuated tube (Vacutainer, Becton Dickenson or Vacuette, Greiner) at the time that the blood sample is obtained from the donor or patient. In some embodiments, the stabilization formulation is added to an already obtained whole blood sample, preferably immediately or shortly after it is withdrawn.
In some embodiments, the methods described herein use the articles of manufacture and kits disclosed.
The following Examples are presented by way of illustration and not limitation.
This Example describes formulations of the present invention for stabilizing inactivated thrombocytes that remain capable of being activated after being stored for a period of 22 hours at ambient temperatures.
Whole blood samples were collected from six human donors using commercially available hirudin-coated collection tubes (Roche Diagnostics), the blood samples were pooled and within three hours of collection, blood samples were processed. A 300 μL aliquot of each whole blood sample was transferred to an Eppendorf tube at a 1:20 ratio with 15 μL of stabilizer formulation A, B, C, or D of Table 1, either prior to or following the addition of the stabilizer formulation, and the mixtures were kept at ambient temperatures for predetermined time periods before being analyzed. An equal volume of whole blood was added to each control sample, and each sample was stored at room temperature in the absence of the stabilizer formulation and processed in parallel with the test samples.
To 300 μL of each mixture and control, 300 μL of NaCl 0.9% and 20 μL of the provided ADP solution was added to promote activation of the thrombocytes and the samples were analyzed using a multiplate analyzer (Roche Diagnostics). Thrombocyte activity in each condition was measured immediately after sample set-up (Time 0) using the multiplate analyzer and ADP test according to the manufacturer's instructions. Thrombocyte activity was also measured at 3 hour, 6 hour, 9 hour and 22 hour time points. Thrombocyte activity in each condition was normalized to its Time 0 measurement. Data from the six donors were then averaged. The data are shown in Table 2.
As shown in Table 2, after the 9 hour incubation period, the mean decrease in thrombocyte activity in the NF control condition was −23% compared with +15%, +14%, +1% and −7% for Formulations A, B, C, and D of Table 2, respectively. After a 22 hour incubation period, significant thrombocyte activity was still detected with a mean decrease in thrombocyte activity in the NF control condition of −41%, compared with −9%, −8%, −26% and −10% for Formulations A, B, C, and D of Table 2, respectively.
Formulations of Table 1 comprising a halogenated disaccharide derivative, sucralose, were characterized as described above, and also were identified as possessing stabilizing thrombocyte activity in whole blood for at least 22 hours (Table 3). In this study, these formulations, as set forth in Table 1, were incorporated into hirudin vacuum blood collection tubes prior to blood draw.
During room temperature blood incubation, thrombocyte activity in the NF control condition decreased by −40% by the 22 hour time point, compared with −3% for Formula E and −27% for Formula F of Table 1.
Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as, “comprises” and “comprising,” which is used interchangeably with “including,” “containing,” or “characterized by,” is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps. The phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular embodiments in which the composition or method consists essentially of or consists of those elements or steps.
Reference throughout this specification to “one embodiment” or “an embodiment” or “an aspect” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
The various embodiments described above can be combined to provide further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
This application is a continuation application of U.S. patent application Ser. No. 15/316,677, filed Dec. 6, 2016, which is a U.S. National Phase Application of International Patent Application No. PCT/US2015/034967, filed Jun. 9, 2015, which claims the benefit of U.S. Provisional Application No. 62/010,151, filed Jun. 10, 2014, all of which are incorporated by reference herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3673158 | Arthur et al. | Jun 1972 | A |
4024548 | Alonso et al. | May 1977 | A |
4040785 | Kim et al. | Aug 1977 | A |
4127502 | Li et al. | Nov 1978 | A |
4185964 | Lancaster | Jan 1980 | A |
4257958 | Powell | Mar 1981 | A |
4264560 | Natelson | Apr 1981 | A |
4342740 | Narra et al. | Aug 1982 | A |
4451569 | Kobayashi et al. | May 1984 | A |
4473552 | Jost | Sep 1984 | A |
4683195 | Mullis et al. | Jul 1987 | A |
4683202 | Mullis | Jul 1987 | A |
4800159 | Mullis et al. | Jan 1989 | A |
4801428 | Homolko et al. | Jan 1989 | A |
4806343 | Carpenter et al. | Feb 1989 | A |
4842758 | Crutzen | Jun 1989 | A |
4889818 | Gelfand et al. | Dec 1989 | A |
4891319 | Roser | Jan 1990 | A |
4898813 | Albarella et al. | Feb 1990 | A |
4933145 | Uchida et al. | Jun 1990 | A |
4962020 | Tabor et al. | Oct 1990 | A |
4962022 | Fleming et al. | Oct 1990 | A |
4965188 | Mullis et al. | Oct 1990 | A |
4978688 | Louderback | Dec 1990 | A |
5039704 | Smith et al. | Aug 1991 | A |
5047342 | Chatterjee | Sep 1991 | A |
5071648 | Rosenblatt | Dec 1991 | A |
5078997 | Hora et al. | Jan 1992 | A |
5079352 | Gelfand et al. | Jan 1992 | A |
5089407 | Baker et al. | Feb 1992 | A |
5096670 | Harris et al. | Mar 1992 | A |
5096744 | Takei et al. | Mar 1992 | A |
5098893 | Franks et al. | Mar 1992 | A |
5147803 | Enomoto | Sep 1992 | A |
5198353 | Hawkins et al. | Mar 1993 | A |
5200399 | Wettlaufer et al. | Apr 1993 | A |
5240843 | Gibson et al. | Aug 1993 | A |
5242792 | Rudolph et al. | Sep 1993 | A |
5270179 | Chatterjee | Dec 1993 | A |
5290765 | Wettlaufer et al. | Mar 1994 | A |
5315505 | Pratt et al. | May 1994 | A |
5351801 | Markin et al. | Oct 1994 | A |
5374553 | Gelfand et al. | Dec 1994 | A |
5397711 | Finckh | Mar 1995 | A |
5403706 | Wilk et al. | Apr 1995 | A |
5409818 | Davey et al. | Apr 1995 | A |
5418141 | Zweig et al. | May 1995 | A |
5428063 | Barak et al. | Jun 1995 | A |
5436149 | Barnes | Jul 1995 | A |
5455166 | Walker | Oct 1995 | A |
5496562 | Burgoyne | Mar 1996 | A |
5498523 | Tabor et al. | Mar 1996 | A |
5512462 | Cheng | Apr 1996 | A |
5516644 | Yamauchi et al. | May 1996 | A |
5529166 | Markin et al. | Jun 1996 | A |
5541290 | Harbeson et al. | Jul 1996 | A |
5556771 | Shen et al. | Sep 1996 | A |
5593824 | Treml et al. | Jan 1997 | A |
5614365 | Tabor et al. | Mar 1997 | A |
5614387 | Shen et al. | Mar 1997 | A |
5684045 | Smith et al. | Nov 1997 | A |
5705366 | Backus | Jan 1998 | A |
5728822 | Macfarlane | Mar 1998 | A |
5741462 | Nova et al. | Apr 1998 | A |
5751629 | Nova et al. | May 1998 | A |
5763157 | Treml et al. | Jun 1998 | A |
5777099 | Mehra | Jul 1998 | A |
5777303 | Berney | Jul 1998 | A |
5779983 | Dufresne et al. | Jul 1998 | A |
5789172 | Still et al. | Aug 1998 | A |
5789414 | Lapidot et al. | Aug 1998 | A |
5798035 | Kirk et al. | Aug 1998 | A |
5814502 | Hoeltke et al. | Sep 1998 | A |
5827874 | Meyer et al. | Oct 1998 | A |
5834254 | Shen et al. | Nov 1998 | A |
5837546 | Allen et al. | Nov 1998 | A |
5856102 | Bierke-Nelson et al. | Jan 1999 | A |
5861251 | Park et al. | Jan 1999 | A |
5863799 | Hengstenberg | Jan 1999 | A |
5874214 | Nova et al. | Feb 1999 | A |
5876992 | De Rosier et al. | Mar 1999 | A |
5914272 | Dufresne et al. | Jun 1999 | A |
5918273 | Horn | Jun 1999 | A |
5939259 | Harvey et al. | Aug 1999 | A |
5945515 | Chomczynski | Aug 1999 | A |
5948614 | Chatterjee | Sep 1999 | A |
5955448 | Colaco et al. | Sep 1999 | A |
5985214 | Stylli et al. | Nov 1999 | A |
5991729 | Barry et al. | Nov 1999 | A |
6013488 | Hayashizaki | Jan 2000 | A |
6015668 | Hughes et al. | Jan 2000 | A |
6017496 | Nova et al. | Jan 2000 | A |
6025129 | Nova et al. | Feb 2000 | A |
6037168 | Brown | Mar 2000 | A |
6050956 | Ikegami et al. | Apr 2000 | A |
6057117 | Harrison et al. | May 2000 | A |
6057159 | Lepre | May 2000 | A |
6071428 | Franks et al. | Jun 2000 | A |
6090925 | Woiszwillo et al. | Jul 2000 | A |
6124089 | Ryan | Sep 2000 | A |
6127155 | Gelfand et al. | Oct 2000 | A |
6143817 | Hallam et al. | Nov 2000 | A |
6153412 | Park et al. | Nov 2000 | A |
6153618 | Schultz et al. | Nov 2000 | A |
6156345 | Chudzik et al. | Dec 2000 | A |
6166117 | Miyazaki | Dec 2000 | A |
6168922 | Harvey et al. | Jan 2001 | B1 |
6197229 | Ando et al. | Mar 2001 | B1 |
6204375 | Lader | Mar 2001 | B1 |
6221599 | Hayashizaki | Apr 2001 | B1 |
6242235 | Shultz et al. | Jun 2001 | B1 |
6251599 | Chen et al. | Jun 2001 | B1 |
6258930 | Gauch et al. | Jul 2001 | B1 |
6284459 | Nova et al. | Sep 2001 | B1 |
6294203 | Burgoyne | Sep 2001 | B1 |
6294338 | Nunomura | Sep 2001 | B1 |
6310060 | Barrett et al. | Oct 2001 | B1 |
6313102 | Colaco et al. | Nov 2001 | B1 |
6322983 | Burgoyne | Nov 2001 | B1 |
6323039 | Dykens et al. | Nov 2001 | B1 |
6329139 | Nova et al. | Dec 2001 | B1 |
6331273 | Nova et al. | Dec 2001 | B1 |
6352854 | Nova et al. | Mar 2002 | B1 |
6366440 | Kung | Apr 2002 | B1 |
6372428 | Nova et al. | Apr 2002 | B1 |
6372437 | Hayashizaki | Apr 2002 | B2 |
6380858 | Yarin et al. | Apr 2002 | B1 |
6416714 | Nova et al. | Jul 2002 | B1 |
6417185 | Goff et al. | Jul 2002 | B1 |
6426210 | Franks et al. | Jul 2002 | B1 |
6440966 | Barrett et al. | Aug 2002 | B1 |
6447726 | Delucas et al. | Sep 2002 | B1 |
6447804 | Burgoyne | Sep 2002 | B1 |
6448245 | Depetrillo et al. | Sep 2002 | B1 |
RE37872 | Franks et al. | Oct 2002 | E |
6458556 | Hayashizaki | Oct 2002 | B1 |
6465231 | Harrison et al. | Oct 2002 | B2 |
6475716 | Seki | Nov 2002 | B1 |
6489344 | Nuss et al. | Dec 2002 | B1 |
6503411 | Franks et al. | Jan 2003 | B1 |
6503702 | Stewart | Jan 2003 | B1 |
6528309 | Levine | Mar 2003 | B2 |
6534483 | Bruno et al. | Mar 2003 | B1 |
6535129 | Petrick | Mar 2003 | B1 |
6602718 | Augello et al. | Aug 2003 | B1 |
6608632 | Daly et al. | Aug 2003 | B2 |
6610531 | Mateczun et al. | Aug 2003 | B1 |
6617170 | Augello et al. | Sep 2003 | B2 |
6627226 | Burgoyne et al. | Sep 2003 | B2 |
6627398 | Wilusz et al. | Sep 2003 | B1 |
6638945 | Gibson | Oct 2003 | B1 |
6645717 | Smith et al. | Nov 2003 | B1 |
6649406 | Williams et al. | Nov 2003 | B1 |
6653062 | Depablo et al. | Nov 2003 | B1 |
6664099 | Worrall | Dec 2003 | B1 |
6667167 | Sorensen et al. | Dec 2003 | B1 |
6682730 | Mickle et al. | Jan 2004 | B2 |
6689353 | Wang et al. | Feb 2004 | B1 |
6696028 | Bara | Feb 2004 | B2 |
6746841 | Fomovskaia et al. | Jun 2004 | B1 |
6746851 | Tseung et al. | Jun 2004 | B1 |
6750059 | Blakesley et al. | Jun 2004 | B1 |
6776959 | Helftenbein | Aug 2004 | B1 |
6787305 | Li et al. | Sep 2004 | B1 |
6800632 | Nuss et al. | Oct 2004 | B2 |
6803200 | Xia et al. | Oct 2004 | B2 |
6821479 | Smith et al. | Nov 2004 | B1 |
6821789 | Augello et al. | Nov 2004 | B2 |
6852833 | Machida et al. | Feb 2005 | B1 |
6858634 | Asrar et al. | Feb 2005 | B2 |
6861213 | Oelmuller et al. | Mar 2005 | B2 |
6862789 | Hering et al. | Mar 2005 | B1 |
6872357 | Bronshtein et al. | Mar 2005 | B1 |
6896894 | Brody et al. | May 2005 | B2 |
6919172 | Depablo et al. | Jul 2005 | B2 |
6942964 | Ward et al. | Sep 2005 | B1 |
6949544 | Bethiel et al. | Sep 2005 | B2 |
6949547 | Nuss et al. | Sep 2005 | B2 |
7001770 | Atencio et al. | Feb 2006 | B1 |
7001905 | Biwersi et al. | Feb 2006 | B2 |
7011825 | Yamazaki et al. | Mar 2006 | B2 |
7037918 | Nuss et al. | May 2006 | B2 |
7045519 | Nuss et al. | May 2006 | B2 |
7049065 | Hayashizaki | May 2006 | B2 |
7083106 | Albany | Aug 2006 | B2 |
7098033 | Chen et al. | Aug 2006 | B2 |
7101693 | Cicerone et al. | Sep 2006 | B2 |
7129242 | Yoshitaka et al. | Oct 2006 | B2 |
7142987 | Eggers | Nov 2006 | B2 |
7150980 | Lapidot et al. | Dec 2006 | B1 |
7169584 | Ward et al. | Jan 2007 | B2 |
7169816 | Barrett et al. | Jan 2007 | B2 |
RE39497 | Franks et al. | Feb 2007 | E |
7172999 | Mattern et al. | Feb 2007 | B2 |
7258873 | Truong-Le et al. | Aug 2007 | B2 |
7270953 | Hollaender et al. | Sep 2007 | B2 |
7282371 | Helftenbein | Oct 2007 | B2 |
7326418 | Franzoso et al. | Feb 2008 | B2 |
7384603 | Klein et al. | Jun 2008 | B2 |
7425557 | Nuss et al. | Sep 2008 | B2 |
7476754 | Herradon et al. | Jan 2009 | B2 |
7521460 | Langham et al. | Apr 2009 | B2 |
7592455 | Brookings et al. | Sep 2009 | B2 |
7728013 | Blatt et al. | Jun 2010 | B2 |
7745663 | Isshiki et al. | Jun 2010 | B2 |
7795256 | Alexander et al. | Sep 2010 | B2 |
7803839 | Aay et al. | Sep 2010 | B2 |
7846703 | Kobayashi et al. | Dec 2010 | B2 |
7897624 | Yan et al. | Mar 2011 | B2 |
7919294 | Franco et al. | Apr 2011 | B2 |
7932266 | Garcia et al. | Apr 2011 | B2 |
7972828 | Ward et al. | Jul 2011 | B2 |
8143271 | Ibrahim et al. | Mar 2012 | B2 |
RE43389 | Helftenbein | May 2012 | E |
8178555 | Chang et al. | May 2012 | B2 |
8378108 | Corkey et al. | Feb 2013 | B2 |
8394822 | Hutchings et al. | Mar 2013 | B2 |
8440665 | Corkey et al. | May 2013 | B2 |
8492427 | Gancia et al. | Jul 2013 | B2 |
8519125 | Whitney et al. | Aug 2013 | B2 |
8530480 | Kamenecka et al. | Sep 2013 | B2 |
8598360 | Corkey et al. | Dec 2013 | B2 |
8642584 | Aftab et al. | Feb 2014 | B2 |
8664244 | Chen | Mar 2014 | B2 |
8827874 | Nishimura | Sep 2014 | B2 |
8900856 | Muller-Cohn et al. | Dec 2014 | B2 |
9078426 | Muller-Cohn et al. | Jul 2015 | B2 |
9376709 | Whitney et al. | Jun 2016 | B2 |
20010038858 | Roser et al. | Nov 2001 | A1 |
20020039771 | Peters et al. | Apr 2002 | A1 |
20020055118 | Eym | May 2002 | A1 |
20020076819 | Bowman et al. | Jun 2002 | A1 |
20020081565 | Barnea et al. | Jun 2002 | A1 |
20020094533 | Hess et al. | Jul 2002 | A1 |
20020103086 | Asrar et al. | Aug 2002 | A1 |
20020182258 | Lunsford et al. | Dec 2002 | A1 |
20020197628 | Stewart | Dec 2002 | A1 |
20030022148 | Seki | Jan 2003 | A1 |
20030031697 | Chudzik et al. | Feb 2003 | A1 |
20030059468 | Mattern et al. | Mar 2003 | A1 |
20030091971 | Xia et al. | May 2003 | A1 |
20030119042 | Franco et al. | Jun 2003 | A1 |
20030129755 | Sadler et al. | Jul 2003 | A1 |
20030138805 | Loffert et al. | Jul 2003 | A1 |
20030157088 | Elliott et al. | Aug 2003 | A1 |
20030162284 | Dordick et al. | Aug 2003 | A1 |
20030163608 | Tiwary et al. | Aug 2003 | A1 |
20030165482 | Rolland et al. | Sep 2003 | A1 |
20030175232 | Elliott et al. | Sep 2003 | A1 |
20030199446 | Bunger et al. | Oct 2003 | A1 |
20030215369 | Eggers et al. | Nov 2003 | A1 |
20040014068 | Burgoyne | Jan 2004 | A1 |
20040058349 | Van Ness et al. | Mar 2004 | A1 |
20040101966 | Davis et al. | May 2004 | A1 |
20040110267 | Sundar | Jun 2004 | A1 |
20040121420 | Smith | Jun 2004 | A1 |
20040121432 | Klein et al. | Jun 2004 | A1 |
20040142475 | Barman et al. | Jul 2004 | A1 |
20040208792 | Linton et al. | Oct 2004 | A1 |
20040228794 | Weller et al. | Nov 2004 | A1 |
20040241713 | Mirzabekov et al. | Dec 2004 | A1 |
20050026181 | Davis et al. | Feb 2005 | A1 |
20050053911 | Greener et al. | Mar 2005 | A1 |
20050084481 | Hand et al. | Apr 2005 | A1 |
20050086822 | Frisner et al. | Apr 2005 | A1 |
20050090009 | Cormier et al. | Apr 2005 | A1 |
20050112610 | Lee et al. | May 2005 | A1 |
20050186254 | Roser et al. | Aug 2005 | A1 |
20050196824 | Fisher et al. | Sep 2005 | A1 |
20050227269 | Lloyd et al. | Oct 2005 | A1 |
20050251501 | Phillips et al. | Nov 2005 | A1 |
20050276728 | Muller-Cohn et al. | Dec 2005 | A1 |
20060014177 | Hogan et al. | Jan 2006 | A1 |
20060099567 | Muller-Cohn et al. | May 2006 | A1 |
20060127415 | Mayeresse | Jun 2006 | A1 |
20060147944 | Chomczynski | Jul 2006 | A1 |
20060177855 | Utermohlen et al. | Aug 2006 | A1 |
20060183687 | Cory et al. | Aug 2006 | A1 |
20060193968 | Keogh et al. | Aug 2006 | A1 |
20060198891 | Ravenelle et al. | Sep 2006 | A1 |
20060210429 | Hunsley et al. | Sep 2006 | A1 |
20060293212 | Griese et al. | Dec 2006 | A1 |
20070020289 | Mattern et al. | Jan 2007 | A1 |
20070043216 | Bair et al. | Feb 2007 | A1 |
20070048726 | Baust et al. | Mar 2007 | A1 |
20070073039 | Chisari | Mar 2007 | A1 |
20070117173 | Levison et al. | May 2007 | A1 |
20070135528 | Butler et al. | Jun 2007 | A1 |
20070212760 | Lapidot et al. | Sep 2007 | A1 |
20070243178 | Ho et al. | Oct 2007 | A1 |
20080050737 | Arieli et al. | Feb 2008 | A1 |
20080064071 | Hogrefe et al. | Mar 2008 | A1 |
20080146790 | Grolz et al. | Jun 2008 | A1 |
20080176209 | Muller et al. | Jul 2008 | A1 |
20080187924 | Korfhage et al. | Aug 2008 | A1 |
20080227118 | Kohno et al. | Sep 2008 | A1 |
20080268514 | Muller et al. | Oct 2008 | A1 |
20080307117 | Muller-Cohn et al. | Dec 2008 | A1 |
20090010858 | Asano | Jan 2009 | A1 |
20090226545 | Blotsky | Sep 2009 | A1 |
20090233283 | Rashtchian et al. | Sep 2009 | A1 |
20090239208 | Mayaudon et al. | Sep 2009 | A1 |
20090259023 | Su et al. | Oct 2009 | A1 |
20090291427 | Muller-Cohn et al. | Nov 2009 | A1 |
20090298132 | Muller-Cohn et al. | Dec 2009 | A1 |
20090312285 | Fischer et al. | Dec 2009 | A1 |
20100099150 | Fang et al. | Apr 2010 | A1 |
20100159528 | Liu et al. | Jun 2010 | A1 |
20100159529 | Metzler et al. | Jun 2010 | A1 |
20100178210 | Hogan et al. | Jul 2010 | A1 |
20100196904 | Arieli et al. | Aug 2010 | A1 |
20100261252 | Long et al. | Oct 2010 | A1 |
20100292447 | Pitner et al. | Nov 2010 | A1 |
20110014676 | Cowan et al. | Jan 2011 | A1 |
20110027862 | Bates et al. | Feb 2011 | A1 |
20110059490 | Lagunavicius et al. | Mar 2011 | A1 |
20110081363 | Whitney et al. | Apr 2011 | A1 |
20110111410 | Ryan | May 2011 | A1 |
20120028933 | Baust et al. | Feb 2012 | A1 |
20120052572 | Whitney et al. | Mar 2012 | A1 |
20120100522 | Saghbini et al. | Apr 2012 | A1 |
20120142070 | Battrell et al. | Jun 2012 | A1 |
20120149004 | Gelfand et al. | Jun 2012 | A1 |
20120282634 | Hughes et al. | Nov 2012 | A1 |
20120295328 | Wyrich et al. | Nov 2012 | A1 |
20130066234 | Helftenbein | Mar 2013 | A1 |
20130209997 | Whitney et al. | Aug 2013 | A1 |
20140017712 | Shoji et al. | Jan 2014 | A1 |
20140065627 | Whitney et al. | Mar 2014 | A1 |
20140261474 | Gonda | Sep 2014 | A1 |
20150329849 | Whitney et al. | Nov 2015 | A1 |
20160135446 | Judy et al. | May 2016 | A1 |
20160338342 | Whitney et al. | Nov 2016 | A1 |
20180352806 | Desharnais et al. | Dec 2018 | A1 |
Number | Date | Country |
---|---|---|
1022441 | Dec 1977 | CA |
2467563 | May 2003 | CA |
101072506 | Nov 2007 | CN |
102026619 | Apr 2011 | CN |
102846541 | Jan 2013 | CN |
102947082 | Feb 2013 | CN |
103384496 | Nov 2013 | CN |
105491883 | Apr 2016 | CN |
2424426 | Mar 1975 | DE |
19834816 | Feb 2000 | DE |
102008029734 | Dec 2009 | DE |
0448146 | Sep 1991 | EP |
0451924 | Oct 1991 | EP |
0493919 | Jul 1992 | EP |
0329822 | Jun 1994 | EP |
0637750 | Feb 1995 | EP |
0706825 | Apr 1996 | EP |
0236069 | May 1997 | EP |
0774464 | May 1997 | EP |
0875292 | Nov 1998 | EP |
0915167 | May 1999 | EP |
1088060 | Apr 2001 | EP |
0833611 | Aug 2001 | EP |
0684315 | Jun 2002 | EP |
0822861 | Nov 2003 | EP |
1555033 | Jul 2005 | EP |
1082006 | Feb 2006 | EP |
0395736 | Aug 2006 | EP |
1736542 | Dec 2006 | EP |
1758932 | Mar 2007 | EP |
1651712 | Oct 2007 | EP |
2934572 | Oct 2015 | EP |
3007556 | Apr 2016 | EP |
3154338 | Apr 2017 | EP |
3155091 | Apr 2017 | EP |
3155395 | Apr 2017 | EP |
2129551 | May 1984 | GB |
S62502633 | Oct 1987 | JP |
H08211065 | Aug 1996 | JP |
H09-87183 | Mar 1997 | JP |
H09127106 | May 1997 | JP |
2000500327 | Jan 2000 | JP |
2001050872 | Feb 2001 | JP |
2009096766 | May 2009 | JP |
4421681 | Feb 2010 | JP |
2012012303 | Jan 2012 | JP |
2012072089 | Apr 2012 | JP |
WO-8607462 | Dec 1986 | WO |
WO-8700196 | Jan 1987 | WO |
WO-8701206 | Feb 1987 | WO |
WO-8900012 | Jan 1989 | WO |
WO-8906542 | Jul 1989 | WO |
WO-9005182 | May 1990 | WO |
WO-9114773 | Oct 1991 | WO |
WO-9200091 | Jan 1992 | WO |
WO-9206188 | Apr 1992 | WO |
WO-9206200 | Apr 1992 | WO |
WO-908349 | May 1992 | WO |
WO-9209300 | Jun 1992 | WO |
WO-9211864 | Jul 1992 | WO |
WO-9206188 | Oct 1992 | WO |
WO 9422885 | Oct 1994 | WO |
WO-9501559 | Jan 1995 | WO |
WO-9502046 | Jan 1995 | WO |
WO-9510605 | Apr 1995 | WO |
WO-9516198 | Jun 1995 | WO |
WO-9610640 | Apr 1996 | WO |
WO-9636436 | Nov 1996 | WO |
WO-9700670 | Jan 1997 | WO |
WO-9705248 | Feb 1997 | WO |
WO-9714785 | Apr 1997 | WO |
WO-9715394 | May 1997 | WO |
WO-9815355 | Apr 1998 | WO |
WO-9824543 | Jun 1998 | WO |
WO 9955346 | Nov 1999 | WO |
WO-9960849 | Dec 1999 | WO |
WO-9967371 | Dec 1999 | WO |
WO-0009746 | Feb 2000 | WO |
WO-0014505 | Mar 2000 | WO |
WO-0020117 | Apr 2000 | WO |
WO-0062023 | Oct 2000 | WO |
WO-0076664 | Dec 2000 | WO |
WO-0137656 | May 2001 | WO |
WO-0194016 | Dec 2001 | WO |
WO-03020874 | Mar 2003 | WO |
WO-03020924 | Mar 2003 | WO |
WO-03056293 | Jul 2003 | WO |
WO-03087335 | Oct 2003 | WO |
WO-2004031363 | Apr 2004 | WO |
WO-2004112476 | Dec 2004 | WO |
WO-2005014704 | Feb 2005 | WO |
WO-2005059178 | Jun 2005 | WO |
WO-2005113147 | Dec 2005 | WO |
WO-2005116081 | Dec 2005 | WO |
WO-2006001499 | Jan 2006 | WO |
WO 2006128022 | Nov 2006 | WO |
WO 2007016352 | Feb 2007 | WO |
WO-2007075253 | Jul 2007 | WO |
WO-2007094581 | Aug 2007 | WO |
WO-2008007463 | Jan 2008 | WO |
WO-2008040126 | Apr 2008 | WO |
WO-2008048228 | Apr 2008 | WO |
WO-2008108549 | Sep 2008 | WO |
WO-2009002568 | Dec 2008 | WO |
WO-2009009210 | Jan 2009 | WO |
WO-2009038853 | Mar 2009 | WO |
WO-2010047592 | Apr 2010 | WO |
WO-2010065924 | Jun 2010 | WO |
WO-2010132508 | Nov 2010 | WO |
WO-2010138522 | Dec 2010 | WO |
WO-2012018638 | Feb 2012 | WO |
WO-2012018639 | Feb 2012 | WO |
WO-2012170907 | Dec 2012 | WO |
WO-2013077290 | May 2013 | WO |
WO-2014049022 | Apr 2014 | WO |
WO-2014100755 | Jun 2014 | WO |
WO-2015002729 | Jan 2015 | WO |
WO-2015191632 | Dec 2015 | WO |
WO-2015191633 | Dec 2015 | WO |
WO-2015191634 | Dec 2015 | WO |
Entry |
---|
“Antibiotics from Prokaryotes.” https://www.boundless.com/microbiology/antimicrobial-drugs/commonly-used-antimicrobial-drugs/antibiotics-from-prokaryotes/, downloaded Aug. 1, 2014. |
“Are supplements with amino acid chelated minerals better than those with other forms of minerals?”. |
“Borax: Friend or foe?” Momsaware.org webpage, http://www.momsaware.org/household-genera1/139-borax-friend-or-foe.html, downloaded Jul. 31, 2014, 1 page. |
“Foods high in glycolic acid.” http://www.ehow.com/list_5815634_foods-high-glycolic-acid.html , downloaded Jul. 31, 2014, 1 page. |
“The dose makes the poison.” Yale chemsafe , (http://learn.caim.yale.edu/chemsafe/references/dose.html, downloaded Aug. 1, 2014, 1 page. |
Allison et al., “Effects of Drying Methods and Additives on Structure and Function of Actin: Mechanisms of Dehydration-Induced Damage and Its Inhibition,” Archives of Biochemistry and Biophysics 358(1):171-181, 1998. |
Anchordoquy et al., “Frontiers in Clinical Research—Preservation of DNA,” Cell Preservation Technology 5(4):180-188, 2007. |
Ando et al., “PLGA Microspheres Containing Plasmid DNA: Preservation of Supercoiled DNA via Cryopreparatin and Carbohydrate Stabilization,” Journ. Pharm. Sci., vol. 88, No. 1, pp. 126-130, 1999. |
Anonymous, “Transmucosal polymeric molecular delivery systems,” retrieved from http://www.antiagingresearch.com/hgh/transmucosal.php on Apr. 7, 2005, 2 pages. |
Arakawa et al., “Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs,” Biochimica et Biophysica Acta 1764:1677-1687, 2006. |
Asano, “Glycosidase inhibitors: update and perspectives on practical use,” Glycobiology 13(10):93R-104R, 2003. |
Balevicius et al., NMR and quantum chemistry study of mesoscopic effects in ionic liquids. J.Phys.Chem., 114:5365-5371, 2010. |
Barnes, The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene, 112:29-35, 1992. |
Baskakov et al., “Forcing Thermodynamically Unfolded Proteins to Fold,” The Journal of Biological Chemistry, 273(9):4831-4834, 1998. |
Boyd et al., “Stabilization Effect of Polyvinyl Alcohol on Horseradish Peroxidase, Glucose Oxidase, 13-Galactosidase and Alkaline Phosphatase,” Biotechnology Techniques 10(9):693-698, 1996. |
Braasch et al. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Bio 8:1-7, 2001. |
Branco et al., Preparation and characterization of new room temperature ionic liquids. Chem.Eur.J. 8:16, p. 3671-3677, 2002. |
Buhler et al., “Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3,” Journal of Virology 75(19):9502-9508, 2001. |
Calfon et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415:92-96, 2002. (Abstract only). |
Carninci et al., “Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA,” Proc. Natl. Acad. Sci. USA 95:520-524, 1998. |
Carpenter et al., “Stabilization of phosphofructokinase during air-drying with sugars and sugar/transition metal mixtures,” Cryobiology 24(5): 455-464, 1987. (Abstract). |
Catalan et al., “Progress towards a generalized solvent polarity scale: The solvatochromism of 2-(dimethylamino)-7-nitrofluorene and its homomorph 2-fluoro-7-nitrofluorene”, Liebigs Ann. 1995(2):241-252, 1995. |
Catalan, Solvent effects based on pure solvent scales. In: Handbook of Solvents. Wypych G., ed. Toronto: ChemTec Publishing and New York: William Andrew Publishing. p. 583-616, 2001. |
Cavalieri et al., “Chaperone-like activity of nanoparticles of hydrophobized poly(vinyl alcohol),” Soft Matter 3:718-724, 2007. |
Chen et al., “Stabilization of Recombinant Human Keratinocyte Growth Factor by Osmolytes and Salts,” Journal of Pharmaceutical Sciences, 85(4):419-426, 1996. |
Cheng et al., “Chip PCR. II. Investigation of different PCR amplification systems in microfabricated silicon-glass chips,” Nucleic Acids Res. 24:380-385, 1996. |
Clement et al. Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabile the binding of DNA polymerase beta to DNA. J. Nat. Prod., 69(3):373-6, 2006. |
Clement et al., Following nature's lead: Generating compounds for stabilizing biomolecules. Biopreservation and Biobanking, 10(4):395-402, 2012. |
Cohen et al., “Diffusion NMR Spectroscopy in Supramolecular and Combinatorial Chemistry: An Old Parameter—New Insights,” Angew. Chem. Int. Ed., 44: 520-554, 2005. |
Dagani, “Stir, Heat—But No Need to Dissolve,” Chemical & Engineering News 81(5): 3 pages, 2003. |
Dankwardt et al., “Stabilization of enzyme immunoassays for atrazine,” Analytica Chimica Acta 362:35-45, 1998. |
Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics,” Advanced Drug Delivery Reviews 58:686-706, 2006. |
De Sanctis et al., “Influence of Glycerol on the Structure and Redox Properties of Horse Heart Cytochrome c. A Circular Dichroism and Electrochemical Study,” Journal of Protein Chemistry, 15(7):599-606, 1996. |
Degim et al., “Controlled Delivery of Peptides and Proteins,” Current Pharmaceutical Design 13:99-117, 2007. |
Del Vigna de Almeida et al., Saliva composition and functions: A comprehensive review. The Journal of Contemporary Dental Practice, 9(3):72-80, 2008. |
DePaz et al., “Effects of drying methods and additives on the structure, function, and storage stability of subtilisin: role of protein conformation and molecular mobility,” Enzyme and Microbial Technology 31:765-774, 2002. |
Di Tullio et al., “Molecular recognition by mass spectrometry,” J. Mass Spectrom, 40(7):845-865, 2005. |
DNA learning center, “Radiation can cause DNA mutations, 3D animation with narration.” http://www.dnalc.org/view/15529-Radiation-can-cause-DNA-mutations-3D-animation-with-narration.html, downloaded Aug. 1, 2014. |
Dong et al., “Biosynthesis of the Validamycins: Identification of Intermediates in the Biosynthesis of Validamycin A by Streptomyces hygroscopicus var. limoneus,” J. Am. Chem. Soc. 123:2733-2742, 2001. |
Dowell et al. Otitis media—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 165-171, 1998. |
Dowell et al. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pedatrics. 101 Suppl. 1: 163-165, 1998. |
Dyke et al., “Solvent-Free Functionalization of Carbon Nanotubes,” J. Am. Chem. Soc. 125:1156-1157, 2003. |
El-Bashiti, “Trehalose Metabolism in Wheat and Identification of Trehalose Metabolizing Enzymes Under Abiotic Stress Conditions,” Thesis, The Graduate School of Natural and Applied Sciences of the Middle East Technical University, Jul. 2003, 140 pages. |
Ellison et al., Buffer capacities of human blood and plasma. Clinical Chemistry, 4(6):452-461, 1958. |
Elzie et al., “The N-terminus of thrombospondin: the domain stands apart,” The International Journal of Biochemistry & Cell Biology 36:1090-1101, 2004. |
EP05778182.5 Office Action dated Apr. 28, 2010. |
EP06848927.7 Office Action dated Jan. 20, 2009. |
EP06848927.7 Office Action dated May 3, 2010. |
EP06848927.7 Office Action dated Nov. 30, 2010. |
EP08826300.9 Supplementary Search Report dated Oct. 26, 2010. |
EP10775442.6 Extended European Search Report dated Jan. 21, 2014. |
EP11815081.2 Communication dated Jan. 4, 2016. |
EP11815081.2 Extended European Search Report dated Nov. 5, 2013. |
EP11815081.2 Office Action dated Jan. 15, 2015. |
EP11815082.0 Communication dated Jan. 4, 2016. |
EP11815082.0 Extended European Search Report dated Nov. 5, 2013. |
EP11815082.0 Office Action dated Jan. 15, 2015. |
EP13865767.1 extended European Search Report dated Oct. 24, 2016. |
EP14819510.0 extended European Search Report dated Feb. 7, 2017. |
EP14819510.0 partial supplementary European Search Report dated Nov. 4, 2016. |
Extended EP Search Report, EP Patent Application No. 21188996.9, mailed Jan. 5, 2022, 9 pages. |
Flaman et al., A rapid PCR fidelity assay. Nucleic Acids Research, 22(15): 3259-3260, 1994. |
Frye et al., “The kinetic basis for the stabilization of staphylococcal nuclease by xylose,” Protein Science, 6:789-793, 1997. |
Galinski et al., “1,4,5,6-Tetrahydro-2-methyl-4-pyrimidinecarboxylic acid. A novel cyclic amino acid from halophilic phototrophic bacteria of the genus Ectothiorhodospira,” Eur. J. Biochem., 149:135-139, 1985. |
Garcia de Castro et al., “Anhydrobiotic Engineering of Gram-Negative Bacteria,” Applied and Environmental Microbiology 66(9):4142-4144, 2000. |
Gerard et al., cDNA synthesis by moloney murine leukemia virus RNase H-minus reverse transcriptase possessing full DNA polymerase activity. Focus, 14(1): 91-93, 1992. |
Godfrey, “Solvent selection via miscibility number,” Chem. Technol. 2(6):359-363, 1972. |
Goller et al., Protection of a model enzyme (lactate dehydrogenase) against heat, urea and freeze-thaw treatment by compatible solute additives, J. of Molecular Catalsys B: Enzymatic, 7(104):37-45, 1999. |
Gombotz et al., “Biodegradable Polymers for Protein and Peptide Drug Delivery,” Bioconjugate Chem. 6:332-351, 1995. |
Gowrishankar et al., Osmoregulation in Enterobacteriaceae: Role of proline/Betaine transport systems. Current Science, 57(5): 225-234, 1988. |
Green DR, “Apoptosis. Death deceiver,” Nature, 396(6712):629-30, 1998. |
Green DR, “Apoptotic pathways: the roads to ruin,” Cell, 94(6):695-69, 1998. |
Green et al., “Mitochondria and apoptosis,” Science, 281(5381):1309-12, 1998. |
Harding et al., Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response. (2000) Mol Cell 5:897-904. |
Haze et al., Mammalian Transcription Factor ATF6 Is Synthesized as a Transmembrane Protein and Activated by Proteolysis in Response to Endoplasmic Reticulum Stress. Mol Biol Cell 10(11):3787-3799, 1999. |
Henke et al., Betaine improves the PCR amplification of GC-rich DNA sequences. Nucleic Acids Research, 25(19): 3957-3958, 1997. |
Hewetson et al., Sucrose concentration in blood: A new method for assessment of gastric permeability in horses with gastric ulceration. J.Vet.Inter.Med., 20:388-394, 2006. |
Hoffman, “Hydrogels for biomedical applications,” Advanced Drug Delivery Reviews 43:3-12, 2002. |
Holland et al., “Biological sample collection and processing for molecular epidemiological studies,” Mutation Research 543:217-234, 2003. |
Holland et al., “Molecular epidemiology biomarkers—Sample collection and processing considerations,” Toxicology and Applied Pharmacology 206:261-268, 2005. |
Houts et al., Reverse transcriptase from avian myeloblastosis virus. Journal of Virology, 29(2): 517-522, 1979. |
https://www.consumerlab.com/answers/Are+supplements+with+amino+acid+chelated+minerals+better+than+those+with+other+forms+of+minerals%3F/amino_acid_mineral_chelates/, downloaded Jul. 31, 2014, 1 page. |
Iyer et al., Enzyme stability and stabilization-Aqueous and non-aqueous environment, Process Biochemistry, 43:1019-1032, 2008. |
Jin et al., Effect of mobile phase additives on resolution of some nucleic compounds in high performance liquid chromatography. Biotechnology and Bioprocess Engineering, 12:525-530, 2007. |
Jones et al., “Long-term storage of DNA-free RNA for use in vaccine studies,” BioTechniques 43(5):675-681, 2007. |
Kaijalainen et al., “An alternative hot start technique for PCR in small volumes using beads of wax-embedded reaction components dried in trehalose,” Nucleic Acids Research 21(12):2959-2960, 1993. |
Kameda et al., “New Cyclitols, Degradation of Validamycin A by Flavobacterium Saccharophilum,” The Journal of Antibiotics 33(12):1573-1574, 1980. |
Kaufman. Orchestrating the unfolded protein response in health and disease. J Clin Invest 110(10):389-1398, 2002. |
Kilger and Paabo, Direct DNA sequence determination from total genomic DNA. Nucleic Acids Research, 25(10): 2032-2034, 1997. |
Kim et al., Chemical Biology Investigation of Cell Death Pathways Activated by Endoplasmic Reticulum Stress Reveals Cytoprotective Modulators of ASK1S. J. Biol. Chem. 284(3):1593-1603, 2009. |
Kirn-Safran et al., “Heparan Sulfate Proteoglycans: Coordinators of Multiple Signaling Pathways during Chondrogenesis,” Birth Defects Research (Part C) 72:69-88, 2004. |
Knapp et al., “Extrinsic protein stabilization by the naturally occurring osmolytes β-hydroxyectoine and betaine,” Extremophiles, 3:191-198, 1999. |
Knuesel et al., “Comparative studies of suidatrestin, a specific inhibitor of trehalases,” Comparative Biochemistry and Physiology Part B 120:639-646, 1998. |
Komiyama et al., “Hydrolysis of DNA and RNA by lanthanide ions: mechanistic studies leading to new applications,” Chem. Commun.: 1443-1451, 1999. |
Konishi et al., “Effects of Bay m 1099, an a-Glucosidase Inhibitor, on Starch Degradation in Germinating Mung Beans,” Biosci. Biotechnol. Biochem. 62(1):142-144, 1998. |
Kotewicz et al., Isolation of closed Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. Nucleic Acid Research, 16(1):265, 1988. |
Kravitz, Lactate: Not guilty as charged. IDEA Fitness Journal 2(6), 23-25, 2005 http://www.unm.edu/lkravitz/Article/%20folder/lactate.html, 3d paragraph, downloaded Jul. 31, 2014. |
Kricka and Wilding, “Microchip PCR,” Anal. Bioanal. Chem 377:820-825, 2003. |
Kudo et al., A molecular chaperone inducer protects neurons from ER stress. Cell Death and Differentiation, 15:364-375, 2008. |
Kumar et al., “The role of proline in the prevention of aggregation during protein folding in vitro,” Biochemistry and Molecular Biology International, 46(3):509-517, 1998. |
Langer, “Polymer-Controlled Drug Delivery Systems,” Acc. Chem. Res. 26:537-542, 1993. |
Langer. New methods of drug delivery. Science, New Series, vol. 249, No. 4976, pp. 1527-1533, 1990. |
Lawyer et al., High-level expression, purification, and enzymatic characterization of full-length Thermus aquaticus DNA polymerase and a truncated form deficient in 5′ to 3′ exonuclease activity. PCR Methods and Applications, Cold Spring Harbor Laboratory Press, 2:275-287, 1993. |
Lee et al., “Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SW, and HIV in vitro and ex vivo,” Proc. Natl. Acad. Sci. USA 95:939-944, 1998. |
Lee et al., “Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants,” J. Am. Chem. Soc. 121:1145-1155, 1999. |
Li et al., “Effect of Mobile Phase Additives on the Resolution of Four Bioactive Compounds by RP-HPLC”, Int'l Journal of Molecular Sciences, 11(5):2229-2240, 2010. |
Liao et al., “The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers,” International Journal of Pharmaceutics 304:29-39, 2005. |
Loo et al., Peptide and Protein Analysis by Electrospray Ionization—MassSpectrometry and Capillary Electrophoresis-Mass Spectrometry, Anal. Biochem., 179(2):404-412, 1989. |
Lou et al., “Increased amplification efficiency of microchip-based PCR by dynamic surface passivation,” Biotechniques, vol. 36, No. 2, pp. 248-252, 2004. |
Lozano et al., Stabilization of x-Chymotrypsin by iconic liquids in transesterification reactions. Biotechnology and Bioengineerig, 75(5):563-569, 2001. |
Luo et al., “Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay,” J. Biotechnol. 65:225, 1998. |
Malin et al., “Effect of Tetrahydropyrimidine Derivatives on Protein-Nucleic Acids Interaction,” The Journal of Biological Chemistry, 274(11):6920-6929, 1999. |
Manzanera et al., “Hydroxyectoine Is Superior to Trehalose for Anhydrobiotic Engineering of Pseudomanas putida KT2440,” Applied and Environmental Microbiology 68(9):4328-4333, 2002. |
Manzanera et al., “Plastic Encapsulation of Stabilized Escherichia coli and Pseudomonas putida,” Applied and Environmental Microbiology 70(5):3143-3145, 2004. |
Marshall et al.,“NXY-059, a Free Radical-Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species,” Stroke, 32:190-198 (2001). |
Mascellani et al., “Compatible solutes from hyperthermophiles improve the quality of DNA microarrays,” BMC Biotechnology, 7(82):1-6, 2007. |
Mitchell et al., “Dispersion of Functionalized Carbon Nanotubes in Polystyrene,” Macromolecules 35:8825-8830, 2002. |
Mizuguchi et al., Characterization and application to hot start PCR of neutralizing momoclonal antibodies against KOD DNA polymerase. J. Biochem., 126:762-768, 1999. |
Mohr, “Reversible chemical reactions as the basis for optical sensors used to detect amines, alcohols and humidity,” J. Mater. Chem., 9:2259-2264, 1999. |
Mori K, Tripartite Management Mini review of Unfolded Proteins in the Endoplasmic Reticulum. Cell 101(5):451-454, 2000. |
Natale et al., Sensitivity of Bovine Blastocyst Gene Expression Patterns to Culture Environments Assessed by Differential Display RT-PCR. Reproduction, 122 (5): 687-693, 2001. |
New England Biolabs 1993/1994, 4 pages. |
Nielsen et al., Peptide nucleis acid (PNA). A DNA mimic with a peptide backbone. Bioconjugate Chemistry, 5:3-7, 1994. |
O'Brien et al. Acute sinusitis—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 174-177, 1998. |
O'Brien et al. Cough illness/bronchitis—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 178-181, 1998. |
Okada et al. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J 366(Pt 2):585-594, 2002. |
Ortega et al., “New functional roles for non-collagenous domains of basement membrane collagens,” Journal of Cell Science 115:4201-4214, 2002. |
Parsegian et al., “Macromolecules and Water: Probing with Osmotic Stress,” Methods in Enzymology, 259:43-94, 1995. |
Passot et al., “Physical characterization of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage,” European Journal of Pharmaceutics and Biopharmaceutics 60:335-348, 2005. |
Pavlov et al., “The Role of ECM Molecules in Activity-Dependent Synaptic Development and Plasticity,” Birth Defects Research (Part C) 72:12-24, 2004. |
PCT/US2005/012084 International Preliminary Report on Patentability dated Oct. 11, 2006. |
PCT/US2005/012084 International Search Report dated Feb. 7, 2006. |
PCT/US2006/45661 International Preliminary Report on Patentability dated Jun. 30, 2008. |
PCT/US2006/45661 International Search Report and Written Opinion dated Nov. 13, 2007. |
PCT/US2008/061332 International Preliminary Report on Patentability dated Oct. 27, 2009. |
PCT/US2008/061332 International Search Report and Written Opinion dated Jul. 29, 2009. |
PCT/US2008/068628 International Preliminary Report on Patentability dated Jan. 5, 2010. |
PCT/US2008/068628 International Search Report and Written Opinion dated Aug. 27, 2009. |
PCT/US2010/34454 International Preliminary Report on Patentability dated Nov. 15, 2011. |
PCT/US2010/34454 International Search Report and Written Opinion dated Jan. 20, 2011. |
PCT/US2011/045404 International Preliminary Report on Patentability dated Jan. 29, 2013. |
PCT/US2011/045404 International Search Report and Written Opinion dated Mar. 27, 2012. |
PCT/US2011/045405 International Preliminary Report on Patentability dated Jan. 29, 2013. |
PCT/US2011/045405 International Search Report and Written Opinion dated Mar. 26, 2012. |
PCT/US2013/077290 International Preliminary Report on Patentability mailed Jul. 2, 2015. |
PCT/US2013/077290 International Search Report and Written Opinion mailed Jun. 23, 2014. |
PCT/US2014/041396 International Search Report mailed Mar. 13, 2015. |
PCT/US2014/042396 International Preliminary Report on Patentability mailed Dec. 23, 2015. |
PCT/US2014/042396 Written Opinion mailed Mar. 13, 2015. |
PCT/US2015/034967 International Search Report and Written Opinion dated Sep. 8, 2015. |
PCT/US2015/034968 International Search Report and Written Opinion Mailed Sep. 16, 2015. |
PCT/US2015/034969 International Preliminary Report on Patentability dated Dec. 22, 2016. |
PCT/US2015/034969 International Search Report and Written Opinion dated Sep. 15, 2015. |
PCT/US2016/065198 International Search Report and Written Opinion dated Mar. 13, 2017. |
PCT/US2016/065200 International Search Report and Written Opinion dated Feb. 16, 2017. |
Peters et al., Sensitivity of human, murine, and rat cells to 5-Fluorouracil and 5′-Deoxy-5-fluorounidine in relation to drug-metabolizing enzymes Cancer Research, 46:20-28, 1986. |
Pickering, LK, Ed. Red Book: Report of the Committee on Infectious Diseases, 26th edition. Elk Grove Village, IL, pp. 695-697, 2003. |
Prestrelski et al., “Dehydration induced Conformational Transitions in Proteins and Their Inhibition by Stabilizers,” Biophysical Journal 65:661-671, 1993. |
Qu et al., Ambient stable quantitative PCR reagents for the detection of Yersinia pestis. PLoS Neglected Tropical Diseases, 4(3):e629, 2010. |
Roberts, “Organic compatible solutes of halotolerant and halophilic microorganisms,” Saline Systems, 1(5):1-30, 2005. |
Roche. “PCR Reaction Components.” Downloaded from the internet (http://www.roche-appliedscience.com/sis/amplification/pcr_amplification_050300.html; Downloaded on Dec. 13, 2012, 4 pages. |
Ron and Walter, Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8:519-529, 2007 (Abstract only). |
Rosenstein et al. The common cold—principles of judicious use of antimicrobial agents. Pediatrics. 101 Suppl. 1: 181-184., 1998. |
Sadeghi et al., Effect of alkyl chain length and temperature on the thermodynamic properties of ionic liquids 1-alkyl-3-methylimidazolium bromide in aqueous and non-aqueous solutions at different temperatures. J.Chem.Thermodynamics, 41:273-289, 2009. |
Saiki et al. Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase. Science 239:487-491, 1988. |
Sauer et al., “Bacterial Milking: A Novel Bioprocess for Production of Compatible Solutes,” Biotechnology and Bioengineering, 57(3):306-313, 1998. |
Sawicki, “Foods high in Glutathione.” http://www.ehow.com/list_6900955_foods-high-glutathione.html, downloaded Jul. 31, 2014, 1 page. |
Schnoor, et al. Characterization of the synthetic compatible solute homoectoine as a potent PCR enhancer. Biochem and Biophys. Res. Comm, 322:867-872, 2004. |
Schwartz et al. Pharyngitis—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 171-174, 1998. |
Schyma et al., “DNA-PCR Analysis of Bloodstains Samples by the Polyvinyl-Alcohol Method,” Journal of Forensic Sciences 44(1):95-99, 1999. |
Schyma et al., “The Accelerated Polyvinyl-Alcohol Method for GSR Collection—PVAL 2.0,” Journal of Forensic Sciences 45(6):1303-1306, 2000. |
Schyma, “Erfahrungen mit der PVAL—Methode in der rechtsmedizinischen Praxis,” Arch. Kriminol. /97(1-2):41-46, 1996. |
Scouten, “A survey of enzyme coupling techniques,” Methods in Enzymology, 135:30-65, 1987. |
Sigma Catalog. St. Louis:Sigma-Aldrich. p. 1987, 1998. |
Sirieix-Plenet et al., “Behaviour of a binary solvent mixture constituted by an amphiphilic ionic liquid, 1-decy1-3-methylimidazolium bromide and water Potentiometric and conductimetric studies,” Talanta 63(4):979-986, Jul. 8, 2004. |
Slita et al., “DNA-polycation complexes Effect of polycation structure on physico-chemical and biological properties,” Journal of Biotechnology, 127:679-693, 2007. |
Smith et al., “Optimal Storage Conditions for Highly Dilute DNA Sampled: A Role for Trehalose as a Preserving Agent,” Journal of Forensic Science 50(5):1-8, 2005. |
Sola-Penna et al., “Carbohydrate protection of enzyme structure and function against guanidinium chloride treatment depends on the nature of carbohydrate and enzyme,” Eur. J. Biochem., 248:24-29, 1997. |
Soltis and Skalka, The alpha and beta chains of avian retrovirus reverse transcriptase independently expressed in Escherichia coli: Characterization of enzymatic activities. Proc. Nat. Acad. Sci. USA, 85:3372-3376, 1968. |
Spiess et al., Trehalose is a potent PCR enhancer: Lowering of DNA melting temperature and thermal stabilization of Taq polymerase by the disaccharide trehalose. Clinical Chemistry, 50:1256-1259, 2004. |
Stein and Moore, The free amino acids of human blood plasma. JCB, 211:915-926, 1954. |
Stock et al., Effects of ionic liquids on the acetylcholinesterase—A structure-activity relationship consideration. Green Chemistry, 6:286-290, 2004. |
Suslick et al., “Colorimetric sensor arrays for molecular recognition,” Tetrahedron 60:11133-11138, 2004. |
The Frontier energy solution, Inc.'s FAQ, http://www.frontierenergysolutionsinc.com/faq/, downloaded Jul. 31, 2014, 1 page. |
Timasheff, “Water as Ligand: Preferential Binding and Exclusion of Denaturants in Protein Unfolding,” Biochemistry, 3/(40:9857-9864, 1992. |
U.S. Appl. No. 11/291,267 Office Action dated Jun. 13, 2014. |
U.S. Appl. No. 12/182,926 Office Action dated Apr. 30, 2014. |
U.S. Appl. No. 13/191,346 Office Action dated Jul. 22, 2014. |
U.S. Appl. No. 11/102,588 Notice of Allowance mailed Sep. 24, 2014. |
U.S. Appl. No. 11/291,267 Office Action dated Mar. 12, 2015. |
U.S. Appl. No. 12/509,303 Office Action dated Jun. 9, 2014. |
U.S. Appl. No. 13/191,346 Office Action dated Jul. 2, 2015. |
U.S. Appl. No. 13/191,346 Office Action dated Mar. 20, 2015. |
U.S. Appl. No. 13/812,288 Office Action dated Aug. 25, 2016. |
U.S. Appl. No. 13/812,288 Office Action dated Feb. 1, 2017. |
U.S. Appl. No. 13/812,288 Office Action dated Feb. 11, 2016. |
U.S. Appl. No. 13/812,288 Office Action dated Jan. 12, 2017. |
U.S. Appl. No. 13/812,288 Office Action dated May 7, 2015. |
U.S. Appl. No. 13/812,288 Restriction Requirement dated Oct. 9, 2014. |
U.S. Appl. No. 13/966,117 Final Office Action dated Feb. 26, 2015. |
U.S. Appl. No. 13/966, 117 Office Action dated Sep. 25, 2014. |
U.S. Appl. No. 14/895,475 Office Action dated Jan. 10, 2017. |
U.S. Appl. No. 14/895,475 Office Action dated May 22, 2017. |
Vanin, “Iron diethyldithiocarbamate as spin trap for nitric oxide detection,” Meth. Enzymol., 301:269-79 (1999). |
Voziyan et al., “Chaperonin-assisted folding of glutamine synthetase under nonpermissive conditions: Off-pathway aggregation propensity does not determine the co-chaperonin requirement,” Protein Science, 9:2405-2412, 2000. |
Wang et al., “A Naturally Occurring Protective System in Urea-Rich Cells: Mechanism of Osmolyte Protection of Proteins against Urea Denaturation,” Biochemistry, 36:9101-9108, 1997. |
Wang et al., “Antibody Structure, Instability, and Formulation,” Journal of Pharmaceutical Sciences 96(1):1-26, 2007. |
Wang et al., “Instability, stabilization, and formulation of liquid protein pharmaceuticals,” International Journal of Pharmaceutics 185:129-188, 1999. |
Wang, “Protein aggregation and its inhibition in biopharmaceutics,” International Journal of Pharmaceutics 289:1-30, 2005. |
Whitman et al., “Prokaryotes: the unseen majority,” Proc. Natl. Acad. Sci. USA, 95:6578-83, 1998. |
Whittlesey et al., “Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface,” Experimental Neurology 190:1-16, 2004. |
Wierzbicka-Patynowski et al., “The ins and outs of fibronectin matrix assembly,” Journal of Cell Science 116:3269-3276, 2003. |
Yamamoto et al., “Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect,” Current Drug Targets 3:123-130, 2002. |
Yancey et al., “Living with Water Stress: Evolution of Osmolyte Systems,” Science, 217:1214-1222, 1982. |
Yang et al., Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia., Exp. Neurol., 163(1):39-45, 2000. |
Yoshida et al., Identification of the cis-Acting Endoplasmic Reticulum Stress Response Element Responsible for Transcriptional Induction of Mammalian Glucose-regulated Proteins: Involvement of basic leucine zipper transcription factors. J Biol Chem 273:33741-33749, 1998. |
Zhao et al., “NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat,” Brain Res., 909(1-2):46-50, 2001. |
Zhi et al., “Renaturation of citrate synthase: Influence of denaturant and folding assistants,” Protein Science, 1:522-529, 1992. |
Number | Date | Country | |
---|---|---|---|
20230363375 A1 | Nov 2023 | US |
Number | Date | Country | |
---|---|---|---|
62010151 | Jun 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16931698 | Jul 2020 | US |
Child | 18202419 | US | |
Parent | 16049516 | Jul 2018 | US |
Child | 16931698 | US | |
Parent | 15316677 | US | |
Child | 16049516 | US |